Ocular Therapeutix (OCUL) Earnings Call Presentation

Retina experience redefined Ocular Therapeutix Corporate Overview April 2025 Forward Looking Statements and Disclaimers Any statements in this presentation about future expectations, plans, and prospects for the Company, including the development and regulatory status of the Company's product candidates, including the design of, and the timing of the enrollment of the Company's SOL-1 and SOL-R Phase 3 clinical trials of AXPAXLI (also called OTX-TKI) for the treatment of wet AMD; the Company's plans to advan ...